Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Cheryl A. Hillery MD
Professor
Department of Pediatrics
Division of Hematology/Oncology

OFFICE ADDRESS:
The Blood Center
P O Box 2178
Milwaukee, WI 53201

EDUCATION:
8/1976 - 5/1980 BS, Biochemistry, University of Wisconsin, Madison, WI
8/1980 - 5/1984 MD, Duke University School of Medicine, Durham, NC

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
7/1984 - 6/1988 Resident, Internal Medicine and Pediatrics, University of North Carolina Hospitals, Chapel Hill, NC
7/1988 - 6/1991 Fellow, Pediatrics and Medicine, Hematology/Oncology (NIH Training grant 7/1989 – 6/1991), University of North Carolina, Chapel Hill, NC
9/1991 - 6/1993 Postdoctoral Fellow, (NIH Training grant 9/1991 – 6/1992), BloodCenter of Wisconsin, Milwaukee, WI

FACULTY APPOINTMENTS:
9/1991 - 6/1993 Instructor, Pediatrics, Medical College of Wisconsin, Milwaukee, WI
7/1993 - 6/2001 Assistant Professor, Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI
7/1993 - 6/2003 Associate Investigator, Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI
7/2001 - 6/2006 Associate Professor, Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI
7/2002 - 6/2006 Associate Professor, Medicine, Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
7/2003 - 2/2012 Investigator, Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI
7/2006 - Present Professor, Pediatrics and Medicine, Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI
11/2011 - Present Professor, Clinical and Translation Science Institute, Medical College of Wisconsin, Milwaukee, WI
2/2012 - Present Senior Investigator, Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI
7/2012 - Present Tenure, Medical College of Wisconsin, Milwaukee, WI

ADMINISTRATIVE APPOINTMENTS:
3/2009 - Present Hematology/Oncology/BMT Leadership Team, Medical College of Wisconsin, Milwaukee, WI

EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:
7/2010 - Present Co-Director, Basic and Translational Sciences, PhD Program, Medical College of Wisconsin, Milwaukee, WI
10/2011 - Present Member/Primary Qualified Master’s Thesis Mentor , CTSI Graduate School of Biomedical Sciences,, Medical College of Wisconsin, Milwuauee, WI

RESEARCH ADMINISTRATIVE APPOINTMENTS:
7/2000 - Present Scientific Director, Wisconsin Sickle Cell Center, Milwaukee, WI
1/2013 - Present Co-Leader, Vascular Biology/ Hematology Research Unit, Children's Research Insitutute,

HOSPITAL STAFF PRIVILEGES:
10/1991 - Present Attending Physician, Hematology, Children's Hospital of Wisconsin, Milwaukee, WI
3/1994 - Present Hematology, Froedtert Hospital, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
American Board of Internal Medicine
1988
None
American Board of Pediatrics
1989
2007
American Board of Pediatrics Hematology-Oncology
1992
2017
 
Licensure
Number Issue DateExpiration
North Carolina
32732
1988
1993
Wisconsin
32582
1992
None
 
AWARDS AND HONORS:
1988 Ciba Geigy Chief Residents Award in Internal Medicine
1990 - 1991 Research Merit Award, Pediatric Evening of Scholarship
1993 - 1998 NIH Career Development Award (K08/CIDA)
1996 Elected to Society of Pediatric Research
2009 - Present Gerry and Heidi Connolly endowed Sickle Cell Professorship, Children's Hospital of Wisconsin
2010 Clinical Physician Award – Clinical Scholarship (Pediatrics)

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
1994 - Present American Society of Hematology (ASH)
1996 - Present Society for Pediatric Research (SPR)
2004 - 2006 Microcirculatory Society (MCS)
2006 - Present American Society of Pediatric Hematology/Oncology (ASPHO)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Editorial Board
2005 - 2010 Blood, journal of the American Society of Hematology (impact factor 10.56)
Journal Review
1995 - Present Ad hoc referee for Blood, JCI, Journal of Biological Chemistry, European Journal of Haematology, Thrombosis Research, Thrombosis and Haemostasis, British Journal of Haematology, etc

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
1999 - Present Appointments and Promotions Committee, Blood Research Institute, BloodCenter of Wisconsin
2003 - 2011 Search Committee for Vascular Biology Investigators, Blood Research Institute, BloodCenter of Wisconsin
2003 - 2004 Search Committee for Executive Vice President for Research and Director of the Blood Reserach Institute, BloodCenter of Wisconsin

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
2001 - 2005 Member, Program Project Grant Parent Review Committee, National Heart, Lung, and Blood Institute (NHLBI)
2004 Ad Hoc Reviewer, Ad hoc reviewer for R01 grant Special Emphasis Panels, National Institute of Health (NIH)
2004 - 2009 Member, Hemoglobin/Red Cell Scientific Committee, American Society of Hematology (ASH)
2005 Ad Hoc Reviewer, Program Project Special Review Committee, National Heart, Lung, and Blood Institute (NHLBI)
2005 Reviewer, Request for Applications Committee (RFA) "Sickle Cell Disease Clinical Research Network”, National Heart, Lung, and Blood Institute (NHLBI)
2006 Ad Hoc Chair, Program Project Special Review Committee, National Heart, Lung, and Blood Institute (NHLBI)
2006 - 2010 Member, Erythrocyte and Leukocyte Biology Study Section, National Institute of Health (NIH)
2008 Member of Panel, Workshop on Sickle Cell Disease - Sub-Committee on Vascular Biology/Pathophysiology, National Heart, Lung, and Blood Institute (NHLBI)
2008 - 2009 Reviewer (2008), Coordinating Reviewer (2009), Sickle Cell Abstract Review for 2008 and 2009 ASH Meetings, American Society of Hematology (ASH)
2008 - 2009 Member of working group, Research Working Group on Sickle Cell Disease, American Society of Pediatric Hematology/Oncology (ASPHO)
2008 Ad Hoc Reviewer, Program Project Special Emphasis Panel , National Heart, Lung, and Blood Institute (NHLBI)
2009 Member of working group, Sickle Cell Disease Workshop—Inflammation, Thrombosis, and Vascular Injury Working Group , National Heart, Lung, and Blood Institute (NHLBI)
2009 Co-Chair, State-of-the-Art Thalassemia Workshop, National Heart, Lung, and Blood Institute (NHLBI)
2009 Ad Hoc Reviewer, ARRA P30 and R13 Grant Review Committees, National Institute of Health (NIH)
2009 Ad Hoc Reviewer, Program Project Special Emphasis Panel, National Heart, Lung, and Blood Institute (NHLBI)
2009 Ad Hoc Reviewer, Grant Review Committee, Wellcome Trust, London England
2011 - Present Ad Hoc Reviewer, SBIR Grant SEP (2011), NHLBI Program Project Grant (1/12 and 10/12); NHLBI SBIR SEP (2/12, chair), NHLBI R24 SEP, Chair (6/13), NHLBI SBIR SEP, Chair (10/13), National Institute of Health (NIH)
2012 - 2015 Member, NHLBI Sickle Cell Disease Advisory Committee , NHLBI, NIH

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
Nociceptive Mechanisms Underlying Sickle Cell Pain
Source:
NIH/NINDS R01 NS070711
Role:
Co-Principal Investigator
PI:
Cheryl Stucky, MD & Cheryl Hillery, MD
Dates:
9/30/2009 - 9/29/2013
Direct Funds:
$1,200,000 (for all years)
 
Title:
Intravenous Magnesium for Sickle Cell Vaso-occlusive Crisis
Source:
NIH/NICHD, R01 HD062347
Role:
Co-Investigator
PI:
David Brousseau, MD
Dates:
4/1/2010 - 2/28/2014
Direct Funds:
$86,000 (Biomarkers Studies and 5% Hillery Effort)
 
Title:
Asthma Increases Vaso-occlusion in Sickle Cell Disease
Source:
NIH/NHLBI, R01 HL102836
Role:
Co-Principal Investigator
PI:
Kirkwood Pritchard, MD & Cheryl Hillery, MD
Dates:
9/1/2010 - 8/31/2014
Direct Funds:
$1,900,986
 
Title:
Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia
Source:
FDA
Role:
Collaborator (Biomarker Studies)
PI:
Joshua field and Micheal DeBaun
Dates:
8/27/2013 - 8/26/2016
 
Prior
Peer Review
Title:
Red blood cell adherence to endothelium in sickle cell disease
Source:
Medical College of Wisconsin Institutional Grant: 3-36566
Role:
Principal Investigator
PI:
Cheryl Hillery
Dates:
1992 - 1993
Direct Funds:
$7,000 (1 year)
 
Title:
Red cell adherence to endothelium in sickle cell disease
Source:
NIH Clinical Investigator Development Award: NIH/NHLBI, K08-HL02858
Role:
Principal Investigator
PI:
Cheryl Hillery
Dates:
1/1/1994 - 12/31/1998
Direct Funds:
$394,500 (for all years)
 
Title:
Mechanisms of stroke in sickle cell disease: sickle red blood cell adhesion to the vascular endothelium
Source:
National American Heart Association Grant-in-Aid: 0050467N
Role:
Principal Investigator
PI:
Cheryl Hillery
Dates:
1/1/2000 - 12/31/2002
Direct Funds:
$215,000 (for all years, terminated early: 6/30/2002)
 
Title:
Red blood cell adhesion in sickle cell disease
Source:
NIH/NHLBI, R01-HL70981
Role:
Principal Investigator
PI:
Cheryl Hillery
Dates:
7/1/2002 - 5/30/2007
Direct Funds:
$900,000 (total for all years)
 
Title:
Minority Supplement for Kimberly Rennie, PhD
Source:
NIH/NHLBI, R01-HL70981S
Role:
Principal Investigator of parent R01
Dates:
6/1/2004 - 5/30/2007
Direct Funds:
$96,547 (toal for all years)
 
Title:
Mechanisms of vaso-occlusion in sickle cell disease: role of coagulation pathways
Source:
NIH/NHLBI, P01-HL44612, Newman Program Project Grant
Role:
Project Leader for Project 3
PI:
Peter Newman, PhD
Dates:
3/1/2005 - 11/30/2010
Direct Funds:
$2,012,492 ($828,492 yr 1-5, plus $1,184,000 yr 5-10, plus Core support for all years; no cost extension through 11/30/2011)
 
Title:
Mechanisms of vaso-occlusion in sickle cell disease: role of coagulation and inflammatory pathways
Source:
NIH/NHLBI, R01-HL080021
Role:
Principal Investigator
PI:
Cheryl Hillery
Dates:
5/1/2005 - 4/30/2010
Direct Funds:
$1,240,000 (awarded for all years, terminated early due to overlap with P01HL44612, $233,600 used)
 
Title:
Asthma and nocturnal hypoxemia in sickle cell anemia
Source:
NIH/NHLBI, R01-HL079937
Role:
Co-Investigator (BCW subcontract PI)
PI:
Michael DeBaun, MD, Washington University
Dates:
8/25/2005 - 6/30/2008
Direct Funds:
$932,071 (for MCW subcontract for all years)
 
Title:
HDL dysfunction and vascular inflammation in sickle cell disease
Source:
NIH/NHLBI, R01-HL081139
Role:
Co-Investigator
PI:
Kirkwood Pritchard, MD
Dates:
4/1/2006 - 3/31/2011
Direct Funds:
$1,250,000 (for all years; no cost extention through 3/31/2012)
 
Title:
Cysteinyl Leukotrienes Receptor Inhibitors: A Target for Decreasing Sickle Cell Disease-Related Morbidity
Source:
Burroughs Wellcome Fund Clinical Scientist Award in Translational Research
Role:
Co-Investigator (MCW & BCW Subcontract PI)
PI:
Michael DeBaun, MD, Washington University
Dates:
7/1/2007 - 6/30/2009
Direct Funds:
$100,000 (for MCW subcontract for all years)
 
Title:
Midwest Basic and Translational Research Program (BTRP)
Source:
NIH/NHLBI U54-HL090503
Role:
Principal Investigator; Core A leader; Project 4 co-Investigator; Summer-for-sickle-cell-science-co-Leader; co-Mentor: Sickle Cell Scholar
PI:
Cheryl Hillery
Dates:
6/15/2008 - 3/31/2012
Direct Funds:
$2,004,980 (for all years)
 
INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
National
1. Adhesion of sickle cells to the vascular endothelium, Red Cells Gordon Research Conference, Tilton, NH, 7/1997
2. Moderator of Simultaneous Session on Sickle Cell Disease, American Society of Hematology (ASH) Annual Meeting, New Orleans, LA, 12/1999
3. Adhesion of erythrocytes to extracellular matrix, American Heart Association Scientific Conference on Interactions of Blood and the Pulmonary Circulation, Sedalia, CO, 9/2000
4. Mechanisms of vaso-occlusion in sickle cell disease, Emory School of Medicine, Atlanta, GA, 8/2003
5. Sickle cell disease: insights into the pathophysiology of vaso-occlusion, New York Blood Center, New York, NY, 10/2003
6. Sickle cell disease: insights into the pathophysiology of vaso-occlusion, Purdue University, LaFayette, IN, 7/2004
7. Role of coagulation and inflammatory pathways in sickle cell vascular disease, Hemostasis Gordon Research Conference, Waterville, ME, 7/2004
8. Sickle cell disease: insights into the pathophysiology of vaso-occlusion, Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, 1/2005
9. Coagulation and Vaso-Occlusion: Which is the Chicken and Which is the Egg” – A Look in to the Crystal Ball: What's in the Future for Sickle Cell Disease, National Sickle Cell Disease Meeting, Cincinnati, OH, 4/2005
10. Moderator for Basic Science Simultaneous Session, National Sickle Cell Disease Meeting, Memphis, TN, 4/2006
11. Sickle Cell Disease: insights into the pathophysiology of vaso-occlusion, University of North Carolina – Chapel Hill, Chapel Hill, NC, 6/2006
12. Coagulation and inflammation in sickle cell disease, Scientific Committee on Thrombosis & Vascular Biology of the American Society of Hematology, Orlando, FL, 12/2006
13. Sickle Cell Disease: insights into the pathophysiology of vaso-occlusion, 2nd Annual Sickle Cell Disease Research and Educational Symposium, Fort Lauderdale, FL, 2/2008
14. Sickle cell disease is an inflammatory disorder, Hemostasis Gordon Research Conference, Waterville Valley, NH, 7/2008
15. Endothelial dysfunction in the sickle cell mouse, Workshop on Vasculopathy in Sickle Cell Disease, National Institutes of Health, Bethesda, MD, 10/2008
16. Sickle Cell Disease is an Inflammatory Disorder: Lessons Learned from Sickle Cell Mice, Cardiopulmonary Symposium on Sickle Cell Disease, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 10/2008
17. Sickle Cell Disease: Inflammation and Thrombosis, Moderator of Simultaneous Session, American Society of Hematology, San Francisco, CA, 12/2008
18. Sickle Cell Disease: Hydroxyurea, Hemoglobin F and Pain, Moderator of Simultaneous Session, American Society of Hematology, New Orleans, LA, 12/2009
19. John I. Hercules, PhD Named Lecture, 5th Annual Sickle Cell Disease Research and Educational Symposium and Annual National Sickle Cell Disease Scientific Meeting, Hollywood, FL, 2/2011
20. Cell Free Hemoglobin, Lipid Oxidation and Nitric Oxide in Sickle Cell Disease, Annual Sickle Cell Disease Clinical Research Meetings: Basic Science & Translational Research Program, NIH Campus, Bethesda, MD, 8/2011
21. Pain and vascular dysfunction in sickle cell disease: insights from sickle mice, Visiting Professorship, Emory University School of Medicine, Atlanta, GA, 9/2011
22. Novel mechanisms of vaso-occlusion in SCD: insights from mouse models, Hematology Oncology Grand Rounds, St Jude Children’s Research Hospital, Memphis, TN, 9/2011
23. Neural and Immune Mechanisms Mediating Pain in Sickle Cell Disease, American Pain Society 33rd Annual Scientific Meeting Symposium, Tampa, FL, 5/2/2014 - Present
 
International
1. Red blood cell adhesion in sickle cell disease, Cambridge University, Cambridge, England, 9/1997
2. Vascular Biology of thrombospondin: Mechanisms of vaso-occlusion in sickle cell disease: adhesion of sickle red cells to thrombospondin, International Conference on the Biology of Thrombospondins, Madison, WI, 6/2000
3. Sickle Cell Disease: insights into the pathophysiology of vaso-occlusion using murine models of sickle cell disease, UK Forum on Haemoglobin Disorders - Plenary Talk, London, England, 10/2006
4. Mouse models in the study of sickle cell disease, Genetics Modifiers of Sickle Cell Disease Explorative Meeting, Wellcome Trust, London, England, 3/2007
5. Potential Novel therapies in Sickle Cell Disease, Bayer Hematology Innovation Summit, Budapest, Hungary, 10/2011
6. Hemoglobinopathies; Progress in Sickle Cell Disease and Beta Thalassemia, Bayer HealthCare Hematology Innovation Summit, Atlanta, Georgia, 12/6/2012 - Present
7. Novel Mechanisms Underlying Pain in Sickle Cell Disease, Bayer HealthCare Hematology Innovation Summit, New Orleans, LA, 12/5/2013 - Present
8. Coagulation and Vascular Pathologies in Mouse Models of Sickle Cell Disease, 60th Meeting of the Scientific & Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis (ISTH), Milwaukee, WI, USA, 6/23/2014 - Present
 
PEER REVIEWED WORKSHOPS/PRESENTATIONS:
National
1. Hillery CA, Du MC, French JA II, Scott JP, Sickle red blood cells bind to the 140 kDa C-terminal domain of thrombospondin, Pediatric Academic Society - Oral Presentation by Cheryl Hillery, Washington, DC, 5/1996
2. Hillery CA, Scott JP, French JA II, Frazier WA, Du MC, Sickle red blood cells bind to the 20 kDa C-terminal domain of thrombospondin, American Society of Hematology (ASH) 38th Annual Meeting - Oral Presentation by Cheryl Hillery, Orlando, FL, 12/1996
3. Hillery CA, Punzalan RC, Trost BA, Scott JP, Hudetz AG, Chondroitin sulfate-A limits cerebral ischemia in sickle erythrocyte-infused rats, 24th Annual Meeting of the National Sickle Cell Disease Program - Oral Presentation by Cheryl Hillery, San Francisco, CA, 3/1999
4. Hillery CA, Du MC, Scott JP, Ware RE, Rogers ZR, Wynn LW, Wang WC, Red blood cell adhesion remains low in very young children with sickle cell disease receiving hydroxyurea therapy, American Society of Hematology (ASH) 41st Annual Meeting - Poster Presentation, New Orleans, LA, 12/1999
5. Punzalan RC, Holzman S, Trost BA, Paszty C, Mohandas N, Scott JP, Hillery CA, Spontaneous stroke and increased erythrocyte adhesion in transgenic knockout sickle cell mice, American Society of Hematology (ASH) 41st Annual Meeting - Poster Presentation, New Orleans, LA, 12/1999
6. Hillery CA, Holzman SL, Mohandas N, Scott JP, Trost BA, Organ-specific fibrin deposition is increased in transgenic sickle mice, 25th Annual Meeting of the National Sickle Cell Disease Program - Poster Presentation, Philadelphia, PA, 3/2000
7. Talano JM, Gottschall JL, Pugh TM, Hillery CA, Scott JP, Partial phenotype matching (Rh, Kell) reduces alloimmuniztion in children with sickle cell disease, American Society of Pediatric Hematology/Oncology (ASPHO) 13th Annual Meeting - Poster Presentation, Minneapolis, MN, 9/2000
8. Wandersee NJ, Olson SC, Holzman SL, Barker JE, Hillery CA, Increased erythrocyte adhesion in mice with hereditary spherocytosis and hereditary elliptocytosis, American Society of Hematology (ASH) 42nd Annual Meeting - Poster Presentation, San Francisco, CA, 12/2000
9. Holzman SL, Shen H, Du LM, Mohandas N, Scott JP, Hudetz A, Hillery CA, Inhibition of nitric oxide synthase induces acute vaso-occlusion in transgenic sickle mice, American Society of Hematology (ASH) 42nd Annual Meeting - Oral Presentation by Cheryl Hillery, San Francisco, CA, 12/2000
10. Vice JL, Le L, Fahs SA, Jozwiak MA, Gill JC, Scott JP, Hillery CA, Montgomery RR, von Willebrand factor gene mutation causing 2A and 2B variants of von Willebrand disease, Pediatric Academic Societies Annual Meeting - Poster Presentation, Baltimore, MD, 5/2001
11. Bayliff SL, Pickens CV, Hillery CA, Ware RE, Changes in surface expression of erythrocyte adhesion molecules in association with hydroxyurea therapy, Pediatric Academic Society Annual Meeting - Oral Presentation by Russell Ware, Baltimore, MD, 5/2001
12. Talano JM, Hillery CA, Gottschall JL, Baylerian DM, Scott JP, Delayed hemolytic transfusion reactions in sickle cell disease, Pediatric Academic Societies Annual Meeting - Poster Presentation, Baltimore, MD, 5/2001
13. Wandersee NJ, Sillah NM, Watkins NA, Scott JP, Ouwehand WH, Hillery CA, Single chain antibody fragments derived from a human phage display library preferentially bind sickle red blood cells and inhibit sickle cell adhesion, American Society of Hematology (ASH) 43rd Annual Meeting - Poster Presentation, Orlando, FL, 12/2001
14. Saunthararajah Y, Molokie R, Lavelle D, HILLERY C, Dorn L, DeSimone J, Subcutaneous 5-aza-2’-deoxycytidine is well tolerated and produces robust increases in fetal hemoglobin, 27th Annual Meeting of the National Sickle Cell Disease Program - Oral Presentation by Yogen Saunthararajah, Washington, DC, 3/2002
15. Hillery CA, Franciosi JP, Ou J, Shi Y, Burglund C, Witte K, Guice K, Oldham KT, Pritchard KA Jr, Increased susceptibility to hypoxic injury in a murine model of sickle cell disease, 27th Annual Meeting of the National Sickle Cell Disease Program - Oral Presentation by Cheryl Hillery, Washington, DC, 3/2002
16. 40.32. Franciosi JP, Pritchard KA Jr, Ou J, Shi Y, Ou Z, Ackland-Berglund C, Witte K, Guice K, Oldham KT, Hillery CA, Increased susceptibility to hypoxic injury in a murine model of sickle cell disease, 9th Annual Meeting of the Oxygen Society - Oral Presentation by Kirkwood Pritchard, San Antonio, TX, 11/2002
17. Hillery CA, Sillah NM, Wandersee NJ, Holzman SL, Gavazova S, Foster TD, Scott JP, Montgomery RR, Saunthararajah Y, DeSimone J, Effect of fetal hemoglobin induction by decitabine on erythrocyte adhesion, coagulation parameters and markers of inflammation in patients with sickle cell disease, American Society of Hematology (ASH) 44th Annual Meeting - Oral Presentation by Cheryl Hillery, Philadelphia, PA, 12/2002
18. Gavazova S, Gill JC, Scott JP, Hillery CA, Friedman KD, Wetzel N, Jozwiak M, Haberichter SL, Christopherson P, Montgomery RR, A mutation in the D4 domain of von Willebrand factor results in a variant of type 1 von Willebrand disease with accelerated in vivo clearance, American Society of Hematology (ASH) 44th Annual Meeting - Oral Presenation by S. Gavazova, Philadelphia, PA, 12/2002
19. Saunthararajah Y, HILLERY C, Lavelle D, Molokie R, Chen A, Dorn L, Hoffman R, DeSimone J, Safety, efficacy and mechanism of action of sub-cutaneous 5-aza-2’-deoxycytidine for elevating fetal hemoglobin levels in patients with sickle cell disease, American Society of Hematology (ASH) 44th Annual Meeting - Poster Presentation, Philadelphia, PA, 12/2002
20. Panepinto JA, Hillery CA, Scott JP, Seasonal variation in hospital length of stay in children with sickle cell disease, American Society of Hematology (ASH) 44th Annual Meeting - Oral Presenation by Julie Panepinto, Philadelphia, PA, 12/2002
21. Hillery CA, Holzman SA, Franciosi JP, Ou J, Ou Z, Mohandas N, Guice K, Oldham KT, Pritchard, KA Jr, Changes in hsp90 - eNOS interactions following hypoxia-induced acute lung injury in a murine model of sickle cell disease, American Society of Hematology (ASH) 44th Annual Meeting - Oral Presenation by Cheryl Hillery, Philadelphia, PA, 12/2002
22. Manci E, Hillery CA, Coller BS, A Systematic Assessment of Organ Pathology in “Berkeley” Sickle Cell Mice: Similarities and differences from human sickle cell disease, American Society of Hematology (ASH) 45th Annual Meeting - Poster Presentation, San Diego, CA, 12/2003
23. Hillery CA, Foster TD, Holzhauer SL, Scott JP, Panepinto JA, Trost BA, Mohandas N, Degen JL, Wandersee NJ, Fibrinogen deficiency decreases hepatic infarction in a stem cell transplant model of murine sickle cell disease, American Society of Hematology (ASH) 45th Annual Meeting - Oral Presentation by Cheryl Hillery, San Diego, CA, 12/2003
24. Brousseau DC, Panepinto JA, Hillery CA, Scott JP, The effect of intravenous magnesium sulfate on length of stay for children hospitalized with sickle cell pain crises, American Society of Hematology (ASH) 45th Annual Meeting - Poster Presentation, San Diego, CA, 12/2003
25. Campanella ME, Anong WA, Wandersee NJ, Hillary CA, Chishti A, Low PS, Characterization of glycolytic enzyme complexes on murine erythrocyte membranes, American Society of Hematology (ASH) 46th Annual Meeting - Poster Presentation, San Diego, CA, 12/2004
26. Wandersee NJ, Punzalan RC, Sillah NM, Rettig MP, Kennedy MD, Scott JP, Low PS, Hillery CA, Modulation of erythrocyte adhesion by changes in cellular tonicity and volume, American Society of Hematology (ASH) 46th Annual Meeting - Poster Presentation, San Diego, CA, 12/2004
27. Gill JC, Rowe R, Conley S, HILLERY C, Panepinto J, Scott JP, Montgomery RR, Desmopressin and Epsilon Amino-Caproic Acid (EACA) in Adenotonsillectomy (T&A): Are we under-treating patients with mild type 1 von Willebrand disease (VWD) and mild platelet function defects (PFD)? , American Society of Hematology (ASH) 46th Annual Meeting - Poster Presentation, San Diego, CA, 12/2004
28. Hillery CA, Foster TD, Holzhauer SL, Scott JP, Panepinto JA, Mohandas N, Mackman N, Wandersee NJ, Tissue factor deficiency decreases sickle cell-induced vascular stasis in a hematopoietic stem cell transplant model of murine sickle cell disease, American Society of Hematology (ASH) 46th Annual Meeting - Oral Presentation by Cheryl Hillery, San Diego, CA, 12/2004
29. Hebbel RP, Jiang A, Hillery CA, Scott JP, Nelson SC, Enenstein J, Milbauer L, Bodempudi V, Pan W, Topper JN, Yang RB, Genetic influence on the systems biology of sickle stroke risk detected by endothelial gene expression, American Society of Hematology (ASH) 47th Annual Meeting - Oral Presentation by R. Hebbel, Atlanta, GA, 12/2005
 
International
1. Wandersee NJ, Punzalan RC, Watkins NA, Ouwehand WH, Low PS, Hillery CA, Role of erythrocyte hydration in adhesion of RBCs to thrombospondin-1, Red Cell Gordon Research Conference - Poster Presentation, Lucca (Barga), Italy, 5/2003
 

BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Hillery CA, Smyth SS, Parise LV Phosphorylation of human platelet glycoprotein IIIa (GPIIIa). Dissociation from fibrinogen receptor activation and phosphorylation of GPIIIa in vitro. J Biol Chem. 1991 Aug 5;266(22):14663-9
2. Smyth SS, Hillery CA, Parise LV Fibrinogen binding to purified platelet glycoprotein IIb-IIIa (integrin alpha IIb beta 3) is modulated by lipids. J Biol Chem. 1992 Aug 5;267(22):15568-77
3. Newman PJ, Hillery CA, Albrecht R, Parise LV, Berndt MC, Mazurov AV, Dunlop LC, Zhang J, Rittenhouse SE Activation-dependent changes in human platelet PECAM-1: phosphorylation, cytoskeletal association, and surface membrane redistribution. J Cell Biol. 1992 Oct;119(1):239-46
4. Chusid MJ, Russler SK, Mohr BA, Margolis DA, Hillery CA, Kehl KC Unsuspected brucellosis diagnosed in a child as a result of an outbreak of laboratory-acquired brucellosis. Pediatr Infect Dis J. 1993 Dec;12(12):1031-3
5. Hillery CA, Du MC, Montgomery RR, Scott JP Increased adhesion of erythrocytes to components of the extracellular matrix: isolation and characterization of a red blood cell lipid that binds thrombospondin and laminin. Blood. 1996 Jun 1;87(11):4879-86
6. Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr. 1996 Jun;128(6):820-8
7. French JA 2nd, Kenny D, Scott JP, Hoffmann RG, Wood JD, Hudetz AG, Hillery CA Mechanisms of stroke in sickle cell disease: sickle erythrocytes decrease cerebral blood flow in rats after nitric oxide synthase inhibition. Blood. 1997 Jun 15;89(12):4591-9
8. Hillery CA, Mancuso DJ, Evan Sadler J, Ponder JW, Jozwiak MA, Christopherson PA, Cox Gill J, Paul Scott J, Montgomery RR Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets. Blood. 1998 Mar 1;91(5):1572-81
9. Hillery CA, Scott JP, Du MC The carboxy-terminal cell-binding domain of thrombospondin is essential for sickle red blood cell adhesion. Blood. 1999 Jul 1;94(1):302-9
10. Punzalan RC, Hillery CA, Montgomery RR, Scott CA, Gill JC Low-molecular-weight heparin in thrombotic disease in children and adolescents. J Pediatr Hematol Oncol. 2000 Mar-Apr;22(2):137-42
11. Hillery CA, Du MC, Wang WC, Scott JP Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br J Haematol. 2000 May;109(2):322-7
12. Bevan JA, Maloney KW, Hillery CA, Gill JC, Montgomery RR, Scott JP Bleeding disorders: A common cause of menorrhagia in adolescents. J Pediatr. 2001 Jun;138(6):856-61
13. Gallagher PG, Chang SH, Rettig MP, Neely JE, Hillery CA, Smith BD, Low PS Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis. Blood. 2003 Jun 1;101(11):4625-7
14. Rice HE, Oldham KT, Hillery CA, Skinner MA, O'Hara SM, Ware RE Clinical and hematologic benefits of partial splenectomy for congenital hemolytic anemias in children. Ann Surg. 2003 Feb;237(2):281-8
15. Watkins NA, Du LM, Scott JP, Ouwehand WH, Hillery CA Single-chain antibody fragments derived from a human synthetic phage-display library bind thrombospondin and inhibit sickle cell adhesion. Blood. 2003 Jul 15;102(2):718-24
16. Ou J, Ou Z, Jones DW, Holzhauer S, Hatoum OA, Ackerman AW, Weihrauch DW, Gutterman DD, Guice K, Oldham KT, Hillery CA, Pritchard KA Jr L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation. 2003 May 13;107(18):2337-41
17. Talano JA, Hillery CA, Gottschall JL, Baylerian DM, Scott JP Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics. 2003 Jun;111(6 Pt 1):e661-5
18. Rathore V, Stapleton MA, Hillery CA, Montgomery RR, Nichols TC, Merricks EP, Newman DK, Newman PJ PECAM-1 negatively regulates GPIb/V/IX signaling in murine platelets. Blood. 2003 Nov 15;102(10):3658-64
19. Saunthararajah Y, Hillery CA, Lavelle D, Molokie R, Dorn L, Bressler L, Gavazova S, Chen YH, Hoffman R, DeSimone J Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood. 2003 Dec 1;102(12):3865-70
20. Melzer-Lange MD, Walsh-Kelly CM, Lea G, Hillery CA, Scott JP Patient-controlled analgesia for sickle cell pain crisis in a pediatric emergency department. Pediatr Emerg Care. 2004 Jan;20(1):2-4
21. Wandersee NJ, Olson SC, Holzhauer SL, Hoffmann RG, Barker JE, Hillery CA Increased erythrocyte adhesion in mice and humans with hereditary spherocytosis and hereditary elliptocytosis. Blood. 2004 Jan 15;103(2):710-6
22. Pritchard KA Jr, Ou J, Ou Z, Shi Y, Franciosi JP, Signorino P, Kaul S, Ackland-Berglund C, Witte K, Holzhauer S, Mohandas N, Guice KS, Oldham KT, Hillery CA Hypoxia-induced acute lung injury in murine models of sickle cell disease. Am J Physiol Lung Cell Mol Physiol. 2004 Apr;286(4):L705-14
23. Brousseau DC, Scott JP, Hillery CA, Panepinto JA The effect of magnesium on length of stay for pediatric sickle cell pain crisis. Acad Emerg Med. 2004 Sep;11(9):968-72
24. Panepinto JA, Brousseau DC, Hillery CA, Scott JP Variation in hospitalizations and hospital length of stay in children with vaso-occlusive crises in sickle cell disease. Pediatr Blood Cancer. 2005 Feb;44(2):182-6
25. Wandersee NJ, Punzalan RC, Rettig MP, Kennedy MD, Pajewski NM, Sabina RL, Paul Scott J, Low PS, Hillery CA Erythrocyte adhesion is modified by alterations in cellular tonicity and volume. Br J Haematol. 2005 Nov;131(3):366-77
26. Manci EA, Hillery CA, Bodian CA, Zhang ZG, Lutty GA, Coller BS Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease. Blood. 2006 Feb 15;107(4):1651-8
27. Ataga KI, Moore CG, Hillery CA, Jones S, Whinna HC, Strayhorn D, Sohier C, Hinderliter A, Parise LV, Orringer EP Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica. 2008 Jan;93(1):20-6
28. Hankins JS, Wynn LW, Brugnara C, Hillery CA, Li CS, Wang WC Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia. Br J Haematol. 2008 Jan;140(1):80-5
29. Chang Milbauer L, Wei P, Enenstein J, Jiang A, Hillery CA, Scott JP, Nelson SC, Bodempudi V, Topper JN, Yang RB, Hirsch B, Pan W, Hebbel RP Genetic endothelial systems biology of sickle stroke risk. Blood. 2008 Apr 1;111(7):3872-9
30. Nandedkar SD, Feroah TR, Hutchins W, Weihrauch D, Konduri KS, Wang J, Strunk RC, DeBaun MR, Hillery CA, Pritchard KA Histopathology of experimentally induced asthma in a murine model of sickle cell disease. Blood. 2008 Sep 15;112(6):2529-38
31. Sabina RL, Wandersee NJ, Hillery CA Ca2+-CaM activation of AMP deaminase contributes to adenine nucleotide dysregulation and phosphatidylserine externalization in human sickle erythrocytes. Br J Haematol. 2009 Feb;144(3):434-45
32. Gladwin MT, Barst RJ, Castro OL, Gordeuk VR, Hillery CA, Kato GJ, Kim-Shapiro DB, Machado R, Morris CR, Steinberg MH, Vichinsky EP Pulmonary hypertension and NO in sickle cell. Blood. 2010 Aug 5;116(5):852-4
33. Nandedkar SD, Weihrauch D, Xu H, Shi Y, Feroah T, Hutchins W, Rickaby DA, Duzgunes N, Hillery CA, Konduri KS, Pritchard KA Jr D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthma. J Lipid Res. 2011 Mar;52(3):499-508
34. Hanson MS, Xu H, Flewelen TC, Holzhauer SL, Retherford D, Jones DW, Frei AC, Pritchard KA Jr, Hillery CA, Hogg N, Wandersee NJ A novel hemoglobin-binding peptide reduces cell-free hemoglobin in murine hemolytic anemia. Am J Physiol Heart Circ Physiol. 2013 Jan;304(2):H328-36
35. Hillery CA, Kerstein PC, Vilceanu D, Barabas ME, Retherford D, Brandow AM, Wandersee NJ, Stucky CL Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease. Blood. 2011 Sep 22;118(12):3376-83
36. Pritchard KA Jr, Feroah TR, Nandedkar SD, Holzhauer SL, Hutchins W, Schulte ML, Strunk RC, Debaun MR, Hillery CA Effects of experimental asthma on inflammation and lung mechanics in sickle cell mice. Am J Respir Cell Mol Biol. 2012 Mar;46(3):389-96
37. Garrison SR, Kramer AA, Gerges NZ, Hillery CA, Stucky CL Sickle cell mice exhibit mechanical allodynia and enhanced responsiveness in light touch cutaneous mechanoreceptors. Mol Pain. 2012 Sep 10;8(1):62
38. Larson MC, Luthi MR, Hogg N, Hillery CA Calcium-phosphate microprecipitates mimic microparticles when examined with flow cytometry. Cytometry A. 2012 Nov 2:
39. Brandow AM, Stucky CL, Hillery CA, Hoffmann RG, Panepinto JA Patients with sickle cell disease have increased sensitivity to cold and heat. Am J Hematol. 2013 Jan;88(1):37-43
40. Hanson MS, Piknova B, Keszler A, Diers AR, Wang X, Gladwin MT, Hillery CA, Hogg N Methaemalbumin formation in sickle cell disease: effect on oxidative protein modification and HO-1 induction. Br J Haematol. 2011 Aug;154(4):502-11
41. Larson MC, Woodliff JE, Hillery CA, Kearl TJ, Zhao M Phosphatidylethanolamine is externalized at the surface of microparticles. Biochim Biophys Acta. 2012 Aug 30:
42. Zhang H, Jing X, Shi Y, Xu H, Du J, Guan T, Weihrauch D, Jones DW, Wang W, Gourlay D, Oldham KT, Hillery CA, Pritchard KA Jr N-Acetyl Lysyltyrosylcysteine Amide Inhibits Myeloperoxidase, a Novel Peptide Based Inhibitor. J Lipid Res. 2013 Jul 24:
43. Zhang H, Xu H, Weihrauch D, Jones DW, Jing X, Shi Y, Gourlay D, Oldham KT, Hillery CA, Pritchard KA Jr Inhibition of myeloperoxidase decreases vascular oxidative stress and increases vasodilatation in sickle cell disease mice. J Lipid Res. 2013 Nov;54(11):3009-15
44. Badaki-Makun O, Scott JP, Panepinto JA, Casper TC, Hillery CA, Dean JM, Brousseau DC, for the Pediatric Emergency Care Applied Research Network (PECARN) Magnesium in Sickle Cell Crisis (MAGiC) Study Group Intravenous magnesium for pediatric sickle cell vaso-occlusive crisis: Methodological issues of a randomized controlled trial. Pediatr Blood Cancer. 2014 Jan 17:
 
Books, Chapters, and Reviews
1. Hillery CA Potential therapeutic approaches for the treatment of vaso-occlusion in sickle cell disease. Curr Opin Hematol. 1998 Mar;5(2):151-5
2. Hillery CA Adhesion of sickle erythrocytes to extracellular matrix. In: EK Weir, HL Reeve, JT Reeves, ed. Interactions of blood and the pulmonary circulations. Armonk, NY: Futura Publishing Company; 2002:68-92
3. Hillery CA, Panepinto JA Pathophysiology of stroke in sickle cell disease. Microcirculation. 2004 Mar;11(2):195-208
4. Hillery CA The chicken or the egg? tissue factor and inflammation in sickle cell disease. “Inside Blood” invited editorial comment. Blood. 2004;104(3):595-596
5. Pritchard KA, Rivera A, Hillery C, Brugnara C. Novel approaches to treatment. In: MH Steinberg, BG Forget, DR Higgs, DJ Weatherall, ed. Disorders of hemoglobin. 2nd ed. New York NY: Cambridge University Press; 2009
6. Ji X, Xu H, Zhang H, Hillery CA, Gao HQ, Pritchard KA Jr Anion Exchange HPLC Isolation of High-Density Lipoprotein (HDL) and On-Line Estimation of Proinflammatory HDL. PLoS One. 2014;9(3):e91089 PMCID: PMC3946658
7. Craig Larson M, Hillery CA, Hogg N Circulating membrane-derived microvesicles in redox biology. Free Radic Biol Med. 2014 Apr 18:
8. Zappia KJ, Garrison SR, Hillery CA, Stucky CL Cold hypersensitivity increases with age in mice with sickle cell disease. Pain. 2014 Jun 3:
9. Ataga KI, Hinderliter A, Brittain JE, Jones S, Xu H, Cai J, Kim S, Pritchard KA, Hillery CA Association of pro-inflammatory high-density lipoprotein cholesterol with clinical and laboratory variables in sickle cell disease. Hematology. 2014 May 6:
 
Abstracts
1. Holzman SL, Shen H, Du LM, Mohandas N, Scott JP, Hudetz A, Hillery CA. Inhibition of nitric oxide synthase induces acute vaso-occlusion in transgenic sickle mice. Blood. 2000; 96:528a
2. Bayliff SL, Pickens CV, Hillery CA, Ware RE. Changes in surface expression of erythrocyte adhesion molecules in association with hydroxyurea therapy. Pediatric Academic Societies' Abstract Acrchive 2001. http://www.abstracts2view.com/pasall/view.php?nu=PAS1L_467
3. Wandersee NJ, Sillah NM, Watkins NA, Scott JP, Ouwehand WH, Hillery CA. Single chain antibody fragments derived from a human phage display library preferentially bind sickle red blood cells and inhibit sickle cell adhesion. Blood. 2001; 98:484a
4. Hillery CA, Holzman SA, Franciosi JP, Ou J, Ou Z, Mohandas N, Guice K, Oldham KT, Pritchard, KA Jr. Changes in hsp90 - eNOS interactions following hypoxia-induced acute lung injury in a murine model of sickle cell disease. Blood. 2002; 100:29a
5. Hillery CA, Sillah NM, Wandersee NJ, Holzman SL, Gavazova S, Foster TD, Scott JP, Montgomery RR, Saunthararajah Y, DeSimone J. Effect of fetal hemoglobin induction by decitabine on erythrocyte adhesion, coagulation parameters and markers of inflammation in patients with sickle cell disease. Blood. 2002; 100:25a
6. Panepinto JA, Hillery CA, Scott JP. Seasonal variation in hospital length of stay in children with sickle cell disease. Blood; 2002; 100:695a
7. Rathore V, HILLERY C, Montgomery RR, Newman PJ. PECAM-1 negatively regulates GPIb/V/IX-induced aggregation of murine platelets. Blood. 2002; 100:1835a
8. Saunthararajah Y, HILLERY C, Lavelle D, Molokie R, Chen A, Dorn L, Hoffman R, DeSimone J. Safety, efficacy and mechanism of action of sub-cutaneous 5-aza-2’-deoxycytidine for elevating fetal hemoglobin levels in patients with sickle cell disease. Blood. 2002; 100:2620a
9. Gavazova S, Gill JC, Scott JP, Hillery CA, Friedman KD, Wetzel N, Jozwiak M, Haberichter SL, Christopherson P, Montgomery RR. A mutation in the D4 domain of von Willebrand factor results in a variant of type 1 von Willebrand disease with accelerated in vivo clearance. Blood. 2002; 100:476a
10. Hillery CA, Foster TD, Holzhauer SL, Scott JP, Panepinto JA, Trost BA, Mohandas N, Degen JL, Wandersee NJ. Fibrinogen deficiency decreases hepatic infarction in a stem cell transplant model of murine sickle cell disease. Blood. 2003; 102:274a
11. Manci E, HILLERY C, Coller BS. A Systematic Assessment of Organ Pathology in “Berkeley” Sickle Cell Mice: Similarities and differences from human sickle cell disease. Blood. 2003; 102:918a
12. Brousseau DC, Panepinto JA, Hillery CA, Scott JP. The effect of intravenous magnesium sulfate on length of stay for children hospitalized with sickle cell pain crises. Blood. 2003; 102:2815a
13. Hillery CA, Foster TD, Holzhauer SL, Scott JP, Panepinto JA, Mohandas N, Mackman N, Wandersee NJ. Tissue factor deficiency decreases sickle cell-induced vascular stasis in a hematopoietic stem cell transplant model of murine sickle cell disease Blood. 2004; 104:236a
14. Wandersee NJ, Punzalan RC, Sillah NM, Rettig MP, Kennedy MD, Scott JP, Low PS, Hillery CA. Modulation of erythrocyte adhesion by changes in cellular tonicity and volume Blood. 2004; 104:1577a
15. Campanella ME, Anong WA, Wandersee NJ, HILLARY CA, Chishti A, Low PS. Characterization of glycolytic enzyme complexes on murine erythrocyte membranes Blood. 2004; 104:1571a
16. Gill JC, Rowe R, Conley S, HILLERY C, Panepinto J, Scott JP, Montgomery RR. Desmopressin and Epsilon Amino-Caproic Acid (EACA) in Adenotonsillectomy (T&A): Are we under-treating patients with mild type 1 von Willebrand disease (VWD) and mild platelet function defects (PFD)? Blood. 2004; 104:1024a
17. Hebbel RP, Jiang A, Hillery CA, Scott JP, Nelson SC, Enenstein J, Milbauer L, Bodempudi V, Pan W, Topper JN, Yang RB. Genetic influence on the systems biology of sickle stroke risk detected by endothelial gene expression. Blood. 2005; 106:73a
18. Pritchard KA Jr, Besch TL, Wang J, Xu H, Jones DW, Foster TD, Holzhauer SL, Oldham KT, Wandersee NJ, Hillery CA. Differential effects of lovastatin and allopurinol therapy in a murine model of sickle cell disease. Blood. 2005; 106:2325a
19. Piknova B, Gladwin M, Hillery CA, Hogg N. Electron Paramagnetic Resonance study of cell-free hemoglobin in sickle cell disease: Potential antioxidant role of haptoglobin. Blood. 2005; 106:549a
20. Sabina RL, Wandersee NJ, Hillery CA. AMP Deaminase activation contributes to accelerated adenine nucleotide pool depletion during periods of energy imbalance in sickle cell erythrocytes. Blood. 2005; 106:1671a
21. Rennie KM, Scott JP, Panepinto JA, Hillery CA. Increased Red Cell Adhesion is Associated with Overt Stroke in Sickle Cell Disease. Blood. 2005; 106:2320a
22. Pritchard KA Jr, Wang J, Xu H, Jones DW, Holzhauer S, Foster TD, Oldham KT, Hillery CA. D-4F restores eNOS-dependent vasodilation by decreasing proinflammatory HDL. Blood. 2005; 106:2324a
23. Hillery CA. Coagulation and Inflammation in Sickle Cell Disease. Blood. 2006; 108a
24. Uy T, Wandersee NJ, Hillery CA. Modifications of the coagulation system alter inflammation in murine sickle cell disease. Blood. 2006; 108: 1242a
25. Brandow AM, Rennie KM, Scott JP, Hillery CA, Panepinto JA. Increased red blood cell adhesion is associated with priapism in sickle cell disease. Blood. 2006; 108: 1235a
26. Hankins J, Wynn L, Brugnara C, HILLERY C, Li CS, Wang W. Phase I study of combination treatment with hydroxyurea and magnesium pidolate in children with sickle cell anemia. Blood. 2006; 108: 686a
27. Wandersee NJ, Frei AC, Holzhauer SL, Scott JP, Pritchard KA Jr, Fagan KA, Hogg N, Hillery CA. Vascular Dysfunction in Murine Models of Hemolytic Anemia. Blood. 2007; 110: 846a
28. Hebbel RP, Wei P, Jiang A, HILLERY C, Scott JP, Nelson SC, Enenstein J, Milbauer L, Bodempudi V, Pan W, Hirsch B, Topper JN, Yang RB. Genetic Influence on the Systems Biology of Sickle Stroke Risk Detected by Endothelial Gene Expression. Blood. 2007; 110: 427a
29. Ataga KI, Hillery CA, Park HA, Moore CG, Jones S, Wang J, Hinderliter A, Pritchard KA Jr. Vascular Dysfunction in Murine Models of Hemolytic Anemia. Proinflammatory Lipids in Sickle Cell Disease-Associated Pulmonary Hypertension. Blood. 2007; 110: 3801a
30. Wandersee NJ, Uy T, Retherford D, Noon-Abdullah A, Frei AC, Brandow AM, Stucky CL, Hillery CA. Mechanical Hypersensitivity in a Mouse Model of Sickle Cell Disease Blood. 2008; 112: 2479a
31. Guo Y, Uy T, Wandersee NJ, Scott JP, Weiler H, Holzhauer S, Retherford D, Foster T, Hillery CA. The Protein C Pathway in Human and Murine Sickle Cell Disease: Alterations in Protein C, Thrombomodulin (TM), and Endothelial Protein C Receptor (EPCR) at Baseline and during Acute Vaso-occlusion Blood. 2008; 112: 538a
32. Guo YH, Field JJ, Foster TD, Scott JP, Wandersee NJ, Hillery CA. Low Molecular Weight Heparin Reduces sVCAM 1 and Lung Congestion in a Murine Model of Sickle Cell Disease. Blood. 2010; 116:1635a
33. Wandersee NJ, Flewelen TC, Frei AC, Jones DW, Retherford DM, Holzhauer SL, Gokuli S, Hanson MS, Hillery CA, Hogg N, Pritchard KA Jr, Xu H. A novel hemoglobin-binding agent reduces plasma free hemoglobin and partially improves vascular function in murine hemolytic anemia. Blood. 2010; 116:267a
34. Flewelen TC, Xu H, Jones DW, Pritchard KA Jr, Hillery CA, Wandersee NJ, Hogg N. Characterizing hE-Hb-B10: A Dual Functioning Hemoglobin Binding Peptide. Free Redical Bio Med. 2011 Nov; 51(Suppl):S86
35. Hanson MS, Flewelen T, Hao Xu, Johnes DW, PA Kirkwood, Hillery CA, Wandersee NJ, Hoagg N. A Novel Hemoglobin Binding Peptide Increases Intracellular Heme and Potentiates Hemoglobin-Induced Heme Oxygenase-1 (HO-1) Levels in Endothelial Cells. Free Redical Bio Med. 2011 Nov; 51(Suppl):S40
36. Brandow AM, Kattappuram R, Hillery CA, Stucky CL, Panepinto JA. Patients with Sickle Cell Disease Have Increased Sensitivity to Cold and Heat Stimuli. Blood 2011; 118: :2116
37. Hanson MS, Flewelen TC, Xu H, Pritchard KA Jr, Wandersee NJ, Hogg N, Hillery CA. A Novel Hemoglobin Binding Peptide Increases Intracellular Heme and Potentiates Hemoglobin-Induced Heme Oxygenase-1 (HO-1) Levels in Endothelial Cells. Blood. 2011; 118:1065